Pyrrolobenzodiazepines and conjugates thereof
A conjugate of formula (A): where Y is selected from a single bond, and a group of formulae A1 or A2: where N shows where the group binds to the N10 of the PBD moiety; R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group; CBA represents a cell binding agent; Q is independently selected from O, S and NH; R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation.
1. A conjugate of formula (A):
the dotted lines indicate the optional presence of a double bond between (a) C1 and C2 or C2 and C3 and (b) C1′ and C2′ or C2′ and C3′;
where R D is independently selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo:
R 7 is independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
Y is selected from a single bond, and a group of formulae A1 or A2:
where N shows where the group binds to the N10 of the PBD moiety;
R L1 and R L2 are independently selected from H and methyl, or together with the carbon atom to which they are bound form a cyclopropylene group;
CBA represents a cell binding agent, wherein the cell binding agent is an antibody or an active fragment thereof;
Q is independently selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
wherein R 16 , R 19 and R 17 are as defined for R 6 , R 9 and R 7 respectively;
wherein R″ is a C 3-12 alkylene group, which chain may be interrupted by one or more heteroatoms selected from O, S, N(H), and NMe and/or aromatic rings, which rings are optionally substituted;
X and X′ are independently selected from O, S and N(H); and
wherein S of the conjugate of formula (A) is linked by a disulfide bond to a free S on the cell binding agent; wherein one of the following conditions (A), (B), and (C) is met:
(A) R 2 is independently selected from ═CH 2 ═CH—R D , or ═C(R D ) 2 , and R 12 is independently selected from H, OH, ═O, CN, R, OR, O—SO 2 —R, CO 2 R and COR; or
(B) R 2 is independently selected from H, OH, ═O, CN, R, OR, O—SO 2 —R, CO 2 R and COR, and R 12 is independently selected from ═CH 2 , ═CH—R D , ═C(R D ) 2 ; or
(C) R 2 and R 12 are each independently selected from H, OH, ═O, CN, methyl, ethyl, propyl, butyl, C 3-12 cycloalkyl, C 2-12 alkynyl, optionally substituted C 3-20 heterocyclyl, optionally substituted C 8-10 aryl, OR, O—SO 2 —R, and CO 2 R COR.
2. The conjugate according to claim 1 , wherein R L1 and R L2 are both H.
3. The conjugate according to claim 1 , wherein R L1 and R L2 are both methyl.
4. The conjugate according to claim 1 , wherein one of R L1 and R L2 is H and the other is methyl.
5. The conjugate according to claim 1 , wherein Y is a single bond.
6. The conjugate according to claim 1 , wherein Y is:
7. The conjugate according to claim 1 , wherein Y is:
8. The conjugate according to claim 1 , wherein R 9 and R 19 are H.
9. The conjugate according to claim 1 , wherein R 6 and R 16 are H.
10. The conjugate according to claim 1 , wherein R 7 are R 17 are both OR 7A , where R 7A is optionally substituted C 1-4 alkyl.
11. The conjugate of claim 10 , wherein R 7A is Me.
12. The conjugate according to claim 1 , wherein X is O.
13. The conjugate according to claim 1 , wherein R 11 is H.
14. The conjugate according to claim 1 , wherein there is a double bond between C2 and C3 and C2′ and C3′ in each monomer unit.
15. The conjugate according to claim 14 , wherein R 2 and R 12 are independently selected from H and R.
16. The conjugate according to claim 15 , wherein R 2 and R 12 are independently R.
17. The conjugate according to claim 16 , wherein R 2 and R 12 are independently optionally substituted C 5-20 aryl.
18. The conjugate according to claim 1 , wherein R 2 is independently selected from ═O, ═CH 2 , ═CH—R D , and ═C(R D )2.
19. The conjugate according to claim 1 , wherein R 11 is a C 3 alkylene group or a C 5 alkylene group.
20. The conjugate according to claim 1 , wherein the antibody or antibody fragment is an antibody or antibody fragment for a tumour-associated antigen.
21. The conjugate of claim 1 wherein the antibody or antibody fragment is an antibody which binds to one or more tumor-associated antigens or cell-surface receptors selected from (1)-(36):
(1) BMPR1B (bone morphogenetic protein receptor-type IB);
(2) E16 (LAT1, SLC7A5);
(3) STEAP1 (six transmembrane epithelial antigen of prostate);
(4) 0772P (CA125, MUC16);
(5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin);
(6) Napi3b (NAPI-38, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b);
(7) Serna 5b (FLJ10372, KIAA1445, Mm.42015, SEMASB, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B);
(8) PSCA hlg (2700050C12Rik, C530008016Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene);
(9) ETBR (Endothelin type B receptor);
(10) MSG783 (RNF124, hypothetical protein FLJ20315);
(11) STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein);
(12) TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4);
(13) CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor);
(14) CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs 73792);
(15) CD79b (CD79B, CD79β, 1Gb (immunoglobulin-associated beta), B29);
(16) FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 1a), SPAP1B, SPAP1C);
(17) HER2;
(18) NCA;
(19) MDP;
(20) IL2ORα;
(21) Brevican;
(22) EphB2R;
(23) ASLG659;
(24) PSCA;
(25) GEDA;
(26) BAFF-R (B cell-activating factor receptor, BLyS receptor 3, BR3);
(27) CD22 (B-cell receptor CD22-B isoform);
(28) CD79a (CD79A, CD79a, immunoglobulin-associated alpha);
(29) CXCR5 (Burkitt's lymphoma receptor 1);
(30) HLA-DOB (Beta subunit of MHC class II molecule (Ia antigen));
(31) P2X5 (Purinergic receptor P2X ligand-gated ion channel 5);
(32) CD72 (B-cell differentiation antigen CD72, Lyb-2);
(33) LY64 (Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family);
(34) FcRH1 (Fc receptor-like protein 1);
(35) IRTA2 (Immunoglobulin superfamily receptor translocation associated 2); and
(36) TENB2 (putative transmembrane proteoglycan).
22. The conjugate of claim 1 wherein the antibody or antibody fragment is a cysteine-engineered antibody.
23. The conjugate of claim 1 wherein the antibody or antibody fragment is an antibody which binds to an ErbB receptor.
24. The conjugate of claim 23 wherein the antibody is trastuzumab.
25. The conjugate of claim 1 wherein Ab is an anti-HER2, an anti-Steap1, or an anti-CD22 antibody.
26. The conjugate according to claim 1 wherein the number of PBD moieties bound to each antibody (Ab) is an integer from 1 to about 8.
27. The conjugate according to claim 26 , wherein the number of PBD moieties to each antibody is 1, 2, 3, or 4.
28. A composition of conjugates as defined in claim 26 comprising a mixture of the antibody-drug conjugate compounds, wherein the average number of PBD moieties per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5.
29. A pharmaceutical composition comprising the conjugate of claim 1 , and a pharmaceutically acceptable diluent, carrier or excipient.
30. The pharmaceutical composition of claim 29 further comprising a therapeutically effective amount of a chemotherapeutic agent.
31. A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 29 .
32. The method of claim 31 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.
33. A compound of formula (D):
and salts and solvates thereof, wherein
the dotted lines indicate the optional presence of a double bond between (a) C1 and C2 or C2 and C3 and (b) C1′ and C2′ or C2′ and C3′;
R 2 , R 6 , R 7 , R 9 , R 12 , R 16 , R 17 , R 19 , X, X′, R″, Y, R L1 and R L2 are as defined in claim 1 .
34. A method of preparing a conjugate according to claim 1 , the method comprising the step of reacting a cell binding agent with compound (D) as defined in claim 33 .
35. An article of manufacture comprising a pharmaceutical composition of claim 29 ; a container; and a package insert or label indicating that the pharmaceutical composition can be used to treat cancer.
36. The conjugate according to claim 1 , wherein, in condition (C), R 2 and R 12 are each independently selected from H, OH, ═O, CN, methyl, ethyl, propyl, butyl, C 3-12 cycloalkyl, C 2-12 alkynyl, OR, O—SO 2 —R and CO 2 R COR.